INTCO MEDICAL(SZ:300677) Zheng Quan Zhi Xing·2025-07-10 12:09Summary of Key Points Core Viewpoint The announcement details the completion of a share buyback and cancellation by Yingke Medical Technology Co., Ltd., which has resulted in a change in the shareholding structure of the company, particularly affecting the stake of the controlling shareholder. Group 1: Share Buyback Overview - The company repurchased 4,504,300 shares, which accounted for approximately 0.6969% of the total share capital before the cancellation [1][2]. - The buyback was conducted using a budget of between RMB 100 million and RMB 200 million, with a maximum repurchase price of RMB 33.03 per share [1]. - The buyback was intended for employee stock ownership plans and/or equity incentives, but the purpose was later changed to reduce registered capital [1][2]. Group 2: Completion of Share Cancellation - The cancellation of the repurchased shares was confirmed to be completed on July 10, 2025, resulting in a reduction of the total share capital from 646,326,180 shares to 641,821,880 shares [2]. - The shareholding structure post-cancellation shows that the proportion of restricted shares increased slightly, while the proportion of unrestricted shares decreased [2]. - The controlling shareholder, Liu Fangyi, increased his shareholding from 35.85% to 36.10% following the cancellation [1][2]. Group 3: Impact on Company Structure - The share buyback and cancellation will not materially affect the company's financial status or operational results, nor will it harm the interests of minority investors [2]. - The company will proceed with necessary legal registrations and amendments to its articles of association following the completion of the share cancellation [3].